Clinical Trials Sponsored by Janssen Pharmaceutica

Total 22193 results

Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures

Epilepsy | Seizures
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine

Migraine Disorders
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal (PsiProsper)

Schizophrenia

Portugal
Janssen-Cilag Farmaceutica Ltda.

Approved for marketing

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia

Brazil
Janssen-Cilag Farmaceutica Ltda.

Completed

An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol

Contraception

Brazil, Mexico
Janssen-Cilag Farmaceutica Ltda.

Completed

An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.

Binge Eating
Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

Bacterial Infections | Helicobacter Infections
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux | Heartburn
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1

HIV

Portugal
Janssen-Cilag Farmaceutica Ltda.

Completed

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

Dementia
Janssen-Cilag Farmaceutica Ltda.

Completed

Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Brazil
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Janssen Pharmaceutical K.K.
Pharmacyclics LLC.

Completed

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Recurrent Mature B-cell Neoplasms

Japan
Janssen Pharmaceutical K.K.
Grünenthal GmbH

Completed

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Pain | Cancer

Japan
Kindai University
Janssen Pharmaceutical K.K.

Recruiting

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan (CUARTET)

Metastatic Castration-sensitive Prostate Cancer

Japan
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
International CTEPH Association
Janssen Pharmaceuticals

Recruiting

TrEatment Approach in the Multimodal Era Registry (TEAM)

Chronic Thromboembolic Pulmonary Hypertension | CTEPH

United States, Denmark, Belgium, Canada, Japan, Argentina, Italy, Austria, Poland, India, Spain, Mexico, United Kingdom, China, Brazil, Turkey, Germany, Singapore, Colombia
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

HIV Infections

Germany, Taiwan, France, United States, Canada, Belgium, Australia, Netherlands, Spain, United Kingdom, Italy, Argentina, Russian Federation
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults

Influenza

United Kingdom
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

HIV Infections

Spain, United States, Canada, Belgium, United Kingdom, Argentina
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Yale University
Janssen Pharmaceutica N.V., Belgium

Completed

Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics

Diabetes Mellitus | Schizophrenia | Bipolar Disorder
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Healthy

United States
Boston Medical Center
Janssen Pharmaceuticals

Completed

Daratumumab for the Treatment of Patients With AL Amyloidosis

AL Amyloidosis

United States
University of Pittsburgh
Janssen Pharmaceuticals

Completed

Risperdal Consta for Bipolar Disorder

Bipolar I Disorder

United States
Dana-Farber Cancer Institute
Janssen Pharmaceutica

Active, not recruiting

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Prostate Cancer

United States
NewVac LLC
Janssen Pharmaceutica N.V., Belgium

Completed

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Ovarian Cancer

Russian Federation
NewVac LLC
Janssen Pharmaceutica N.V., Belgium

Completed

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

Russian Federation
Universitaire Ziekenhuizen KU Leuven
Janssen Pharmaceutica

Completed

Investigating the Effectiveness of Exercise Coaching on the Physical Activity Behavior of Physically Inactive Employees.

Sedentary Lifestyle

Belgium
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

HIV Infections

Germany, Spain, United States, Canada, Taiwan, France, Italy, Argentina, United Kingdom, Russian Federation, Australia
University of Washington
Janssen Pharmaceuticals

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Active, not recruiting

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Healthy

United States
University Hospital, Lille
Janssen Pharmaceuticals

Terminated

Changes in Body Composition Under Ustekinumab in PsA (STELARA-CC)

Psoriatic Arthritis

France
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
OncoVerity, Inc.
Janssen Pharmaceutical K.K.; argenx

Completed

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute

Japan
Peking University
Xian-Janssen Pharmaceutical Ltd.

Unknown

The Third Survey of Prescription Pattern of Psychotropic Drugs in China

Prescription

China
University Hospital, Lille
Janssen Pharmaceutica N.V., Belgium

Not yet recruiting

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01)

Multiple Myeloma
ANRS, Emerging Infectious Diseases
Janssen Pharmaceuticals

Completed

Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (MOBIDIP)

HIV Infection

Cameroon, Burkina Faso, Senegal
University of Alabama at Birmingham
Janssen Pharmaceutica

Completed

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

Borderline Personality Disorder

United States
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
University of Miami
Amgen; Janssen Pharmaceuticals

Recruiting

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)

Multiple Myeloma

United States, Sweden
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine

Clinical Trials Sponsored by Janssen Pharmaceutica

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations